导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -10.89% | 3820/4773 |
| 近一周 | -4.39% | 4973/5462 |
| 近一月 | -4.18% | 2279/5421 |
| 近一季 | -5.07% | 1759/5209 |
| 近半年 | -10.44% | 3637/4920 |
| 近一年 | -18.32% | 3862/4366 |
| 近两年 | 35.79% | 2059/2954 |
| 近三年 | 10.49% | 1734/2253 |
| 成立以来 | 44.83% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.51% 3642/4961 |
-8.82% 3923/5312 |
- - |
- - |
| 2025 | 26.31% 60/358 |
9.43% 116/340 |
6.98% 164/348 |
20.19% 86/354 |
-10.23% 253/358 |
| 2024 | 6.34% 201/329 |
-6.58% 216/280 |
2.62% 179/310 |
17.45% 102/318 |
-5.56% 243/329 |
| 2023 | -16.65% 180/275 |
-2.60% 167/205 |
-5.16% 175/230 |
-6.48% 184/262 |
-3.51% 220/276 |
| 2022 | -15.03% 68/201 |
-13.54% 104/153 |
7.05% 45/164 |
-21.00% 124/189 |
16.19% 37/202 |
| 2021 | -12.95% 72/150 |
2.77% 112/312 |
7.54% 102/328 |
-11.11% 227/358 |
-11.39% 132/151 |
| 2020 | 13.96% 34/103 |
-13.53% 171/280 |
12.59% 144/295 |
4.03% 108/299 |
12.53% 86/305 |
| 2019 | 28.69% 23/88 |
16.98% 31/258 |
-2.79% 226/268 |
-0.22% 154/253 |
13.42% 20/266 |
| 2018 | -16.65% 60/79 |
- - |
- - |
- - |
-13.32% 150/241 |
| 2017 | 34.37% 6/69 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华宝香港中小(QDII-LOF)A VS. 长安沪深300非周期A(740101) |